I

117TH CONGRESS
2D SESSION

H. R. 8976

To preempt State restrictions on dispensing mifepristone or misoprostol, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 22, 2022

Mr. RYAN of New York introduced the following bill; which was referred to the Committee on Energy and Commerce

---

A BILL

To preempt State restrictions on dispensing mifepristone or misoprostol, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ''Protecting Reproductive Freedom Act''.

SEC. 2. PREEMPTION OF STATE RESTRICTIONS ON DISPENSING MIFEPRISTONE AND MISOPROSTOL.

No State may establish, implement, or enforce—

(1) any prohibition or restriction on shipping or sending mifepristone or misoprostol across State lines;

(2) any requirement that mifepristone or misoprostol be dispensed by a health care practitioner in person; or

(3) any prohibition or restriction on prescribing or dispensing mifepristone or misoprostol by means of telehealth.

SEC. 3. REPORT.

Not later than 30 days after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall submit a report to the Congress on ways to expand access to abortion medication.

SEC. 4. DEFINITIONS.

In this Act:

(1) The term ''mifepristone'' means mifepristone that is—

(A) approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355);

(B) indicated for medical abortion; and

(C) subject to a risk evaluation and mitigation strategy under section 505–1 of the Fed-

eral Food, Drug, and Cosmetic Act (21 U.S.C. 355–1).

(2) The term ''misoprostol'' means misoprostol that is—

(A) approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355);

(B) indicated for medical abortion; and

(C) subject to a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1).

○